CYP2C19 variation, not citalopram dose nor serum level, is associated with QTc prolongation.

Abstract excerpt

Recently, a FDA Safety Communication warned of a dose-dependent risk for QTc prolongation with citalopram, which is metabolized by CYP2C19 of the cytochrome P450 system. We investigate associations between citalopram and escitalopram dose, serum concentration, CYP2C19 phenotype, and QTc. We undertook a retrospective chart review of citalopram or escitalopram patients with the inclusion criteria of consistent...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Arrhythmias, Cardiac
• Share to Brugada Syndrome
• Share to Cardiac Conduction System Disease